Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $305,945.20 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 6,820 shares of Pro-Dex stock in a transaction on Friday, January 17th. The stock was sold at an average price of $44.86, for a total transaction of $305,945.20. Following the sale, the director now owns 344,683 shares in the company, valued at $15,462,479.38. This represents a 1.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pro-Dex Stock Up 0.0 %

Shares of NASDAQ:PDEX opened at $44.35 on Monday. The company’s fifty day moving average is $48.26 and its 200-day moving average is $33.06. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. Pro-Dex, Inc. has a 52 week low of $16.18 and a 52 week high of $59.60. The company has a market capitalization of $144.58 million, a PE ratio of 28.80 and a beta of 0.56.

Hedge Funds Weigh In On Pro-Dex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PDEX. Ritholtz Wealth Management bought a new position in shares of Pro-Dex in the fourth quarter valued at approximately $572,000. Dimensional Fund Advisors LP increased its holdings in Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares in the last quarter. Geode Capital Management LLC raised its position in Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares during the last quarter. Bard Associates Inc. boosted its stake in Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after purchasing an additional 2,031 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PDEX. Ascendiant Capital Markets lifted their target price on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.